王储

主持和参与的科研项目：                    
1.国家自然科学基金委员会，青年科学基金项目，82002138，用于艾滋病治疗的新型双功能CD8⁺ T细胞调控系统的建立与效果评价，2021.01-2023.12，24万元，在研，主持                                        
2.吉林省科学技术厅，吉林省科技发展计划，20210508041RQ，急性感染期选择性突变对艾滋病病毒适应性影响机制的研究，2021.07-2023.06，10万元，在研，主持                                        
3.国家自然科学基金委员会，面上项目，31970888，SHIV感染恒河猴体内产生针对HIV-1广谱中和抗体机制的研究，2020.01-2023.12，59万元，在研，参与                                        
4.中华人民共和国科学技术部， “十三五”国家科技重大专项增补项目，2018ZX10731101-001-020，可诱导广谱中和抗体的gp120蛋白三聚体研究，2019.01-2020.12，200万元，结题，参与                    
5.中国博士后科学基金会，第64批面上项目，2018M641786，SHIV感染恒河猴产生抗HIV-1高效bnAbs的分离与特性研究，2019.01- 2020.12，5万元，结题，主持                    
6.中国博士后科学基金会，博士后创新人才支持计划，BX20180124，SHIV感染恒河猴体内产生的抗HIV-1高效广谱中和抗体的分离与特性研究，2018.07-2020.12，20万元，结题，主持                    
7.国家自然科学基金委员会，面上项目，31670162，高度选择性突变对艾滋病病毒适应性影响机制的研究，2017.01-2020.12，68万元，结题，参与                    
代表性论著：                    
1. Gao N, Gai Y, Meng L,Wang C, Wang W, Li X, Gu T, Louder MK, Doria-Rose NA, Wiehe K, Nazzari AF, Olia AS, Gorman J, Rawi R, Wu W, Smith C, Khant H, de Val N, Yu B, Luo J, Niu H, Tsybovsky Y, Liao H, Kepler TB, Kwong PD, Mascola JR, Qin C, Zhou T, Yu X*, Gao F*. Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. Advanced Science. 2022, 9(15):e2200063.                    

2.Wang C^#, Meng L^#, Wang J, Zhang K, Duan S, Ren P, Wei Y, Fu X, Yu B, Wu J*, Yu X*. Role of Intracellular Distribution of Feline and Bovine SAMHD1 Proteins in Lentiviral Restriction.Virol Sin. 2021, 36(5):981-996.

3.Wang C, Zhang K, Meng L, Zhang X, Song Y, Zhang Y, Gai Y, Zhang Y, Yu B, Wu J, Wang S, Yu X*. The C-terminal domain of feline and bovine SAMHD1 proteins has a crucial role in lentiviral restriction.J Biol Chem. 2020, 295(13):4252-4264.
4.Wang C^#, Liu D^#, Zuo T, Hora B, Cai F, Ding H, Kappes J, Ochsenbauer C, Kong W, Yu X, Bhattacharya T, Perelson AS, Gao F*. Accumulated mutations by 6 months of infection collectively render transmitted/founder HIV-1 significantly less fit.J Infect. 2020, 80(2):210-218.                    
5. Gao N, Gai Y, Meng L,Wang C, Zhang X, Wang W, Qin C, Yu X*, Gao F*. Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques.Viruses. 2020, 12(2):163.

6.Wang C^#, Gao N^#, Song Y, Duan S, Wang W, Cong Z, Qin C, Jiang C, Yu X*, Gao F*. Reduction of peak viremia by an integration-defective SIV proviral DNA vaccine in rhesus macaques.Microbiol Immunol. 2020, 64(1):52-62.

7. Gao N^#, Wang W^#,Wang C^#, Gu T, Guo R, Yu B, Kong W, Qin C, Giorgi EE, Chen Z, Townsley S, Hu SL, Yu X*, Gao F*. Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection.AIDS. 2018, 32(5):555-563.

8. Liu D^#,Wang C^#, Hora B, Zuo T, Goonetilleke N, Liu MKP, Berrong M, Ferrari G, McMichael AJ, Bhattacharya T, Perelson AS, Gao F*. A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies.Retrovirology. 2017, 14(1):46.

9.Wang C, Jiang C, Gao N, Zhang K, Liu D, Wang W, Cong Z, Qin C, Ganusov VV, Ferrari G, LaBranche C, Montefiori DC, Kong W, Yu X*, Gao F*. Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine.Viruses. 2017, 9(6):135.                    

10.Wang C, Liu D, Guo X, Yu B, Wu H, Zhang H, Wu J, Jiang C, Kong W*, Yu X*. Antiviral activity of a zymolytic grain based extract on human immunodeficiency virus type 1 in vitro.Evid Based Complement Alternat Med. 2015, 2015:642327.